Drug Pipeline
Our periodic gene therapy report helps payor better understand the potential for these innovative treatments to transform patient care and outcomes More
Briefing
“High-Cost Drugs”
58 result(s)
Cost Management
Changes to CVS Caremark template formularies effective January 1, 2021 continue our legacy of innovation as well as delivering value and quality care — helping clients save money... More
Briefing
Cost Management
As part of the CVS Health hyperinflation strategy, our Outlier Pharmacy Program proactively monitors and identifies pharmacies with increased volume in claims submissions of... More
Briefing
Cost Management
In 2019, drug trend for CVS Caremark pharmacy benefit clients was a historically low, industry-leading 1.4 percent, with 41% of clients seeing negative trend. Specialty trend was... More
Feature
Cost Management
CVS Health offers payors a new stop-loss program and installment payment plan to help mitigate the large one-time impact of costly gene therapies. These approaches are part of... More
Briefing
Cost Management
Gene therapies have the potential to relieve tremendous suffering for patients with genetic disorders and together we can find ways to ensure these treatments are accessible for... More
White Paper
Care Management
Payors can better manage oncology costs by optimizing therapy regimen selection using evidence-based guidelines directly integrated into our proprietary Novologix platform. More
Video
Cost Management
Payors are projected to save on per-member-per-month costs from strategic formulary removals designed to help mitigate the effect of high-cost and hyperinflationary drugs More
Briefing
Specialty
CVS Health uses its integrated model to manage specialty spend across benefits and help positively impact clinical and financial outcomes. More
Briefing
Drug Pipeline
Biosimilars are a critical tool PBMs can use to help increase market competition and lower costs – we made changes to our template formularies for categories that now have... More
Feature